Wooridul Huebrain Limited (118000.KS)
KRW 316.0
(-1.25%)
KRW 316.0
(-1.25%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -16.72 Billion KRW | -354.7% |
| 2022 | 6.56 Billion KRW | 122.35% |
| 2021 | -29.38 Billion KRW | -367.37% |
| 2020 | 10.98 Billion KRW | 129.76% |
| 2019 | 4.78 Billion KRW | 198.82% |
| 2018 | -4.84 Billion KRW | -165.75% |
| 2017 | 7.36 Billion KRW | -12.37% |
| 2016 | 8.4 Billion KRW | 203.96% |
| 2015 | 2.76 Billion KRW | -56.88% |
| 2014 | 6.4 Billion KRW | 124.89% |
| 2013 | 2.84 Billion KRW | 168.26% |
| 2012 | -4.17 Billion KRW | -118.0% |
| 2011 | 23.19 Billion KRW | -46.09% |
| 2010 | 43.02 Billion KRW | 262.99% |
| 2009 | 11.85 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -36.86 Billion KRW | -120.39% |
| 2024 Q2 | -47.5 Billion KRW | -28.84% |
| 2023 Q2 | 8.94 Billion KRW | 64.38% |
| 2023 Q1 | 5.44 Billion KRW | -17.11% |
| 2023 FY | -16.72 Billion KRW | -354.7% |
| 2023 Q3 | -11.24 Billion KRW | -225.67% |
| 2023 Q4 | -16.72 Billion KRW | -48.74% |
| 2022 Q3 | 10.89 Billion KRW | -26.8% |
| 2022 Q1 | -11.11 Billion KRW | 62.18% |
| 2022 FY | 6.56 Billion KRW | 122.35% |
| 2022 Q4 | 6.56 Billion KRW | -39.71% |
| 2022 Q2 | 14.88 Billion KRW | 233.9% |
| 2021 Q1 | 28.93 Billion KRW | 163.29% |
| 2021 Q3 | 76 Million KRW | -99.68% |
| 2021 Q4 | -29.38 Billion KRW | -38758.03% |
| 2021 Q2 | 24.01 Billion KRW | -17.02% |
| 2021 FY | -29.38 Billion KRW | -367.37% |
| 2020 Q2 | 1.59 Billion KRW | -82.49% |
| 2020 Q4 | 10.98 Billion KRW | 194.81% |
| 2020 FY | 10.98 Billion KRW | 129.76% |
| 2020 Q1 | 9.11 Billion KRW | 90.67% |
| 2020 Q3 | -11.59 Billion KRW | -826.09% |
| 2019 Q1 | 1.26 Billion KRW | 126.19% |
| 2019 Q2 | 11.89 Billion KRW | 838.77% |
| 2019 FY | 4.78 Billion KRW | 198.82% |
| 2019 Q3 | 9.21 Billion KRW | -22.52% |
| 2019 Q4 | 4.78 Billion KRW | -48.12% |
| 2018 Q4 | -4.84 Billion KRW | -188.65% |
| 2018 Q3 | 5.46 Billion KRW | 257.16% |
| 2018 Q2 | 1.52 Billion KRW | -58.85% |
| 2018 FY | -4.84 Billion KRW | -165.75% |
| 2018 Q1 | 3.71 Billion KRW | -49.53% |
| 2017 Q1 | 5.55 Billion KRW | -33.87% |
| 2017 Q4 | 7.36 Billion KRW | -35.63% |
| 2017 FY | 7.36 Billion KRW | -12.37% |
| 2017 Q2 | 7.31 Billion KRW | 31.63% |
| 2017 Q3 | 11.43 Billion KRW | 56.39% |
| 2016 Q2 | 8.43 Billion KRW | 425.32% |
| 2016 FY | 8.4 Billion KRW | 203.96% |
| 2016 Q4 | 8.4 Billion KRW | 14.56% |
| 2016 Q3 | 7.33 Billion KRW | -13.07% |
| 2016 Q1 | 1.6 Billion KRW | -41.9% |
| 2015 FY | 2.76 Billion KRW | -56.88% |
| 2015 Q3 | 2.75 Billion KRW | 98.44% |
| 2015 Q2 | 1.38 Billion KRW | -79.36% |
| 2015 Q1 | 6.73 Billion KRW | 5.07% |
| 2015 Q4 | 2.76 Billion KRW | 0.22% |
| 2014 Q4 | 6.4 Billion KRW | 2.94% |
| 2014 FY | 6.4 Billion KRW | 124.89% |
| 2014 Q3 | 6.22 Billion KRW | 40.83% |
| 2014 Q2 | 4.42 Billion KRW | 142.03% |
| 2014 Q1 | 1.82 Billion KRW | -35.91% |
| 2013 FY | 2.84 Billion KRW | 168.26% |
| 2013 Q4 | 2.84 Billion KRW | 0.0% |
| 2012 Q2 | 7.81 Billion KRW | 1.86% |
| 2012 Q3 | 7.99 Billion KRW | 2.33% |
| 2012 Q4 | -4.17 Billion KRW | -152.2% |
| 2012 FY | -4.17 Billion KRW | -118.0% |
| 2012 Q1 | 7.67 Billion KRW | -66.91% |
| 2011 Q4 | 23.19 Billion KRW | -54.83% |
| 2011 Q3 | 51.34 Billion KRW | -3.19% |
| 2011 FY | 23.19 Billion KRW | -46.09% |
| 2011 Q1 | 59.08 Billion KRW | 37.33% |
| 2011 Q2 | 53.03 Billion KRW | -10.23% |
| 2010 FY | 43.02 Billion KRW | 262.99% |
| 2010 Q3 | 40.52 Billion KRW | -0.64% |
| 2010 Q1 | 12.23 Billion KRW | 0.0% |
| 2010 Q4 | 43.02 Billion KRW | 6.16% |
| 2010 Q2 | 40.78 Billion KRW | 233.27% |
| 2009 FY | 11.85 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Daewoong Co., Ltd. | 315.57 Billion KRW | 105.301% |
| PharmGen Science, Inc. | 1.05 Billion KRW | 1681.274% |